FDA approved Myhibbin (mycophenolate mofetil) for Organ Rejection ProphylaxisFDA approved new liquid and capsule form of transplant rejection drug

Myhibbin (mycophenolate mofetil) is an antimetabolite immunosuppressant. It is a prodrug of mycophenolic acid, which inhibits inosine monophosphate dehydrogenase, a key enzyme in the de novo synthesis of guanine nucleotides. This selectively inhibits lymphocyte proliferation, thereby suppressing cell-mediated immune responses and antibody formation.

Myhibbin is indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart, or liver transplants, in combination with other immunosuppressants.

- **Important Administration:** Should be used under supervision of a physician experienced in immunosuppressive therapy. Not interchangeable with mycophenolic acid delayed-release tablets. Avoid skin/mucous membrane contact; wash with soap and water if contact occurs, rinse eyes with plain water. Administer on an empty stomach; may be taken with food in stable patients. Do not mix with liquids prior to administration. Can be given via nasogastric tube (minimum 8 French). Missed dose: take as soon as remembered unless within 2 hours of next dose. - **Adult Kidney Transplant:** 1 g orally twice daily (total 2 g/day). - **Adult Heart Transplant:** 1.5 g orally twice daily (total 3 g/day). - **Adult Liver Transplant:** 1.5 g orally twice daily (total 3 g/day). - **Pediatric Kidney Transplant (3 months and older):** 600 mg/m² orally twice daily, maximum 2 g/day (or 10 mL oral suspension). - **Pediatric Heart Transplant (3 months and older):** Starting dose 600 mg/m² twice daily; may increase to 900 mg/m² twice daily if tolerated (maximum 3 g/day or 15 mL oral suspension). - **Pediatric Liver Transplant (3 months and older):** Starting dose 600 mg/m² twice daily; may increase to 900 mg/m² twice daily if tolerated (maximum 3 g/day or 15 mL oral suspension). - **Dosage Modifications:** In kidney transplant patients with severe chronic graft impairment (GFR <25 mL/min/1.73 m²), do not exceed 1 g twice daily. For neutropenia (ANC <1.3 x 10³/µL), interrupt or reduce dosing, perform diagnostic tests, and manage appropriately.

Trial data not available in label. The label references clinical studies for mycophenolate mofetil in kidney, heart, and liver transplantation, but specific efficacy data for Myhibbin are not provided.

Specific warnings and contraindications are not detailed in the provided label text. However, the label notes that Myhibbin should not be used without supervision of a physician experienced in immunosuppressive therapy. It also warns against interchangeability with mycophenolic acid delayed-release tablets. For neutropenia, dosing interruption or reduction is recommended. (Note: Full prescribing information would contain additional warnings, but they are not included in the provided text.)

Myhibbin provides an alternative formulation of mycophenolate mofetil for prophylaxis of organ rejection in kidney, heart, and liver transplant recipients. It is used in combination with other immunosuppressants. Clinicians should consider individual patient factors, including organ type, age, renal function, and hematologic status when dosing. Due to lack of interchangeability with delayed-release mycophenolic acid, careful prescribing and patient counseling are essential.